The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride
OBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIA...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Urologia
2008-10-01
|
| Series: | International Brazilian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000500003 |
| _version_ | 1818084253504634880 |
|---|---|
| author | Konstantinos N. Stamatiou Paraskevi Zaglavira Andrew Skolarikos Frank Sofras |
| author_facet | Konstantinos N. Stamatiou Paraskevi Zaglavira Andrew Skolarikos Frank Sofras |
| author_sort | Konstantinos N. Stamatiou |
| collection | DOAJ |
| description | OBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIALS AND METHODS: This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) > 40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months). RESULTS: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. CONCLUSIONS: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH. |
| first_indexed | 2024-12-10T19:50:57Z |
| format | Article |
| id | doaj.art-a672db37a96c45b9ba284095d5adddec |
| institution | Directory Open Access Journal |
| issn | 1677-5538 1677-6119 |
| language | English |
| last_indexed | 2024-12-10T19:50:57Z |
| publishDate | 2008-10-01 |
| publisher | Sociedade Brasileira de Urologia |
| record_format | Article |
| series | International Brazilian Journal of Urology |
| spelling | doaj.art-a672db37a96c45b9ba284095d5adddec2022-12-22T01:35:47ZengSociedade Brasileira de UrologiaInternational Brazilian Journal of Urology1677-55381677-61192008-10-0134555556210.1590/S1677-55382008000500003The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasterideKonstantinos N. StamatiouParaskevi ZaglaviraAndrew SkolarikosFrank SofrasOBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIALS AND METHODS: This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) > 40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months). RESULTS: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. CONCLUSIONS: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000500003prostatebenign prostate hyperplasiavolumePSAstatinsfinasteride |
| spellingShingle | Konstantinos N. Stamatiou Paraskevi Zaglavira Andrew Skolarikos Frank Sofras The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride International Brazilian Journal of Urology prostate benign prostate hyperplasia volume PSA statins finasteride |
| title | The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| title_full | The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| title_fullStr | The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| title_full_unstemmed | The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| title_short | The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| title_sort | effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride |
| topic | prostate benign prostate hyperplasia volume PSA statins finasteride |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000500003 |
| work_keys_str_mv | AT konstantinosnstamatiou theeffectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT paraskevizaglavira theeffectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT andrewskolarikos theeffectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT franksofras theeffectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT konstantinosnstamatiou effectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT paraskevizaglavira effectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT andrewskolarikos effectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride AT franksofras effectsoflovastatinonconventionalmedicaltreatmentoflowerurinarytractsymptomswithfinasteride |